BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, Aieta M, Pastina I, Di Fabio F, Bertolini A, Corsi DC, Mogavero S, Angelini V, Pazzagli M, Di Costanzo F. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. World J Gastroenterol 2015; 21(23): 7281-7288 [PMID: 26109816 DOI: 10.3748/wjg.v21.i23.7281]
URL: https://www.wjgnet.com/1007-9327/full/v21/i23/7281.htm
Number Citing Articles
1
Nuttavut Sumransub, Kornpong Vantanasiri, Ajay Prakash, Emil Lou. Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?Molecular Therapy - Oncolytics 2021; 22: 1 doi: 10.1016/j.omto.2021.05.001
2
Toshikazu Moriwaki, Masahiko Gosho, Akinori Sugaya, Takeshi Yamada, Yoshiyuki Yamamoto, Ichinosuke Hyodo. Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without Bevacizumab in Patients with Metastatic Colorectal Cancer: A Meta-AnalysisCancer Research and Treatment 2021; 53(3): 703 doi: 10.4143/crt.2020.805
3
Yaping Chen, Xiao Zheng, Changping Wu. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal CancerFrontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.792691